Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.133 EUR | -0.72% | +0.39% | +38.90% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-03 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 4.56B 4.95B 388B | Sales 2025 * | 4.34B 4.71B 370B | Capitalization | 12.62B 13.71B 1,075B |
---|---|---|---|---|---|
Net income 2024 * | 1.76B 1.91B 150B | Net income 2025 * | 1.56B 1.7B 133B | EV / Sales 2024 * | 2.77 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.91 x |
P/E ratio 2024 * |
7.27
x | P/E ratio 2025 * |
7.57
x | Employees | - |
Yield 2024 * |
5.76% | Yield 2025 * |
6.11% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 week | +0.39% | ||
1 month | +2.38% | ||
3 months | +19.62% | ||
6 months | +26.53% | ||
Current year | +38.90% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 31/12/15 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 31/08/13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 18/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 21/01/21 |
James Pettigrew
CHM | Chairman | 65 | 27/10/21 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 26/10/16 |
Date | Price | Change |
---|---|---|
04/06/24 | 5.165 | -0.10% |
03/06/24 | 5.17 | 0.00% |
31/05/24 | 5.17 | +0.88% |
30/05/24 | 5.125 | +1.59% |
29/05/24 | 5.045 | -1.37% |
Delayed Quote Börse Stuttgart, June 04, 2024 at 07:10 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.65% | 580B | |
+18.44% | 312B | |
+15.97% | 252B | |
+20.56% | 207B | |
+20.65% | 182B | |
+24.83% | 169B | |
+8.94% | 164B | |
+10.51% | 154B | |
-13.23% | 144B |
- Stock Market
- Equities
- A5G Stock
- A5G Stock